QuartzBio secures Eir Partners investment for trial intelligence platform

QuartzBio has secured a strategic investment and majority ownership from Eir Partners to expedite its clinical trial intelligence platform. QuartzBio's platform is designed to address challenges in clinical development operations. QuartzBio will provide advanced analytics and benchmarking, enabling multi-trial decision-making. Credit: SaiArLawKa2 / Shutterstock.com. QuartzBio has secured a strategic investment and majority ownership from private equity company Eir Partners to expedite its clinical trial intelligence platform. The move marks a significant step as QuartzBio strengthens its role as a foundation for biopharma companies focused on optimising operational efficiency and enhancing data control in clinical trials. NPVM: BioNTech SE's BNT-115 Reports…

Source: Clinical Trials Arena